Follow-up studie R±IFN: Long-term outcome and the post-treatment effects of rituximab administered as single agent or in combination with Interferon-α2a in patients with follicular or other low-grade (indolent) lymphoma
Follow-up studie R±IFN: Long-term outcome and the post-treatment effects of rituximab administered as single agent or in combination with Interferon-α2a in patients with follicular or other low-grade (indolent) lymphoma
Project number : 249541
Created by: Ylva Storck, 2018-06-13
Last revised by: Ylva Storck, 2018-06-13
Project created in: FoU Region Örebro län

CompletedCompleted

PUL-anmälan

  1. Follow-up studie R±IFN: Long-term outcome and the post-treatment effects of rituximab administered as single agent or in combination with Interferon-α2a in patients with follicular or other low-grade (indolent) lymphoma, PUL-anmälan
  2. Follow-up studie R±IFN: Long-term outcome and the post-treatment effects of rituximab administered as single agent or in combination with Interferon-α2a in patients with follicular or other low-grade (indolent) lymphoma, Projektbeskrivning

Titel och sammanfattning

Populärvetenskaplig sammanfattning

Syftet är att fastställa långtidsöverlevnad (OS) hos lymfompatienter som deltog i 2 tidigare studier

(M39035 & ML16865)

Sammanfattning på engelska

"This is an open ended observational follow-up study that will continue until one of the following has been documented for all enrolled patients: withdrawal from the study, lost to follow-up or Death, whichever occurs first"

Projektspecifik information

Ämnesord

checked Cancer och onkologi


(Only selected options are displayed. Click here to display all options)

Studietyp

Observationsstudie

Fas

IV

Randomiserad studie

Nej

Diagnoskod

C81-C96 Maligna tumörer i lymfatisk, blodbildande och besläktad vävnad

Multicenterstudie

Ja

EPN diarienr

2015/2018-32

Biobankstillstånd

Finns ej

Strålskyddstillstånd

Ej aktuellt

Planerat startdatum

2015-10-01

Planerat slutdatum

2017-11-21

Studiens status

Projektet avslutat

Inklusionsstatus

 Planerat antalAntal tillfrågadeScreen-failureAntal randominserade
n=   14 inkluderade

Vetenskaplig sammanfattning

Syftet är att fastställa långtidsöverlevnad (OS) hos lymfompatienter som deltog i 2 tidigare studier

(M39035 & ML16865)

Involverade parter

Arbetsplats

information Added workplaces
Landsting - Region Örebro Län - Hälso- och sjukvård - Område opererande och onkologi - Onkologiska kliniken workplace verified by Region Örebro län on 2018-02-27

Nationell koordinator

information Added workplaces
Landsting - Stockholms läns landsting - Karolinska Universitetssjukhuset - Onkologi Thorax - Hematologiskt Centrum

Slutrapport

Slutdatum

2017-11-21

Follow-up studie R±IFN: Long-term outcome and the post-treatment effects of rituximab administered as single agent or in combination with Interferon-α2a in patients with follicular or other low-grade (indolent) lymphoma, from FoU Region Örebro län
http://www.researchweb.org/is/en/fourol/project/249541